FeesSafety
Pluang+

Ozempic market to hit $113.95B by 2032 with 24.9% CAGR driven by rising diabetes and metabolic health demand.

Market News
06 Nov 2026, 21:00 WIB
Mordor Intelligence
View Source
Bullish
Ozempic market to hit $113.95B by 2032 with 24.9% CAGR driven by rising diabetes and metabolic health demand.

The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, and expanding healthcare access globally. North America leads the market, while Asia-Pacific shows strong growth potential. Challenges include treatment affordability and supply chain management, but digital healthcare and manufacturing investments support market expansion.

The Ozempic market's projected growth to USD 113.95 billion by 2032 provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 20:42 WIB: out of 150 priced US health-sector stocks, 51 rose and 94 fell today. Notably, TMDX gained 11.93% with a typical hold time of 26 days and 100% buy order activity, contrasting with XRAY's 13.97% drop and BKD's 11.66% decline.

More News

BriaCell and BriaPro reveal promising preclinical immunotherapy data at SITC 2026.

BriaCell and BriaPro reveal promising preclinical immunotherapy data at SITC 2026.

BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...

Others
Bullish
17 minutes ago
IMUNON's IMNN-001 boosts anti-tumor T-cell activity, improving survival in advanced ovarian cancer Phase 2 trial.

IMUNON's IMNN-001 boosts anti-tumor T-cell activity, improving survival in advanced ovarian cancer Phase 2 trial.

IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...

Market News
Bullish
17 minutes ago
Canary Capital launches first U.S. spot staked INJ ETF on Nasdaq, offering exposure plus staking rewards.

Canary Capital launches first U.S. spot staked INJ ETF on Nasdaq, offering exposure plus staking rewards.

Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...

Market News
Bullish
17 minutes ago
Minerva Neurosciences reports Q3 2026 results; Phase 3 trial of roluperidone for schizophrenia negative symptoms ongoing.

Minerva Neurosciences reports Q3 2026 results; Phase 3 trial of roluperidone for schizophrenia negative symptoms ongoing.

Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...

Company Fundamentals
Bullish
17 minutes ago
Nexans to supply 420 km cable for Greece's major 1 GW Corinth-Kos power link

Nexans to supply 420 km cable for Greece's major 1 GW Corinth-Kos power link

Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App